Cartesian Therapeutics (RNAC) stock

Market cap $223MShares as of Jul 31

$7.36
+1.94%

Market closed. Prices as of Friday's close.

Not scored

Breakaway doesn't score RNAC. It is too thinly traded for a fair Quality Score.

Healthcare · Biotech

Next2H 2026“This clinical trial is expected to initiate in the second half of 2026…”Trial start · 8-K, Aug 6
Cash$148M, about 7 quarters at the last year's spendingOn Jun 30 · the company says “into 2028”

Follow RNAC's trial news. Pro members can get an alert when Cartesian Therapeutics files news, and see its trials, share raises, and its CEO's filings.

Get an optional alert when RNAC files news on its trialsSee it live, free for 24 hours. No account needed. Then keep going with a free account.
Cash$148M, about 7 quarters at the last year's spendingOn Jun 30 · the company says “into 2028”

We do the work for you. 3,243 stocks are scored and ranked, every 15 seconds while the market is open. Pro members see it live. So can you, free, with no account.

What's next for RNAC, and how long its cash lasts

From Cartesian Therapeutics’s SEC filings and ClinicalTrials.gov: the company’s own words, the registry’s dates, and arithmetic, not a forecast. Companies often miss their own dates.

Next step the company has named

2H 2026“This clinical trial is expected to initiate in the second half of 2026 with in-human data expected in the first half of 2027.”Trial start · 8-K, Aug 6

What it means: when a trial begins, or reaches the stage the company named.

A trial underway
Investigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Approach to Treat Myasthenia GravisPhase 3 · Active · 128 people · main data estimated Dec 30, 2026 · NCT06799247

4 more trials, 1 with data due this year, 2 more milestones and 47 filings, for Pro members.

Cash runway Jun 30 balance sheet

About 7 quarters

$148M in cash and short-term investments, at its spending over the last year

What it means: how long the cash would last at the same pace, before any new money. The company's own estimate is “into 2028” (8-K, Aug 6).

For Pro members: the cash used each quarter, and the math.

Dilution on the horizon

  • Shelf registration (S-3, filed Dec 13, 2024)
  • At-the-market share sales program (424B3, filed Jan 8, 2025)

A shelf lets a company sell shares later; an at-the-market program sells them into the market over time. Neither is a sale by itself.

For Pro members: 1 raise and its amount, and the share count against a year ago.

Insiders

CEO Carsten Brunn sold 23,766 shares on Jan 6. 2 more insider trades this year.

From their own Form 4 filings: buys and sales in the market, not awards or shares withheld for tax.

For Pro members: every trade, and Carsten Brunn’s 10 filings and quotes.

Get an optional alert when RNAC files news on its trialsSee it live, free for 24 hours. No account needed. Then keep going with a free account.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their own filings, soonest first and small companies first.

DateStockDrug

8 more FDA dates and 114 trial data dates in the next 60 days. Pro members see every one, with the cash against its date and an optional alert before it. Get in free →

RNAC's latest filings

26 more filings in the last year, for Pro members

From SEC EDGAR, as filed. Each opens the filing on the SEC's site.

Why RNAC isn't scored

The Quality Score reads US-listed stocks worth $50M or more that trade at $1 or more and 300,000 shares a day. RNAC trades about 121,000 shares a day. A stock that clears every mark is scored from the next weekly rebuild.

Straight Answers

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, trial included, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.

Where does the data come from?

Daily bars, quotes, reference data, headlines, and short interest come from Massive, formerly Polygon, a licensed market data vendor. The age of the quotes is shown at the top of every page. Insider trades, notable holders and profits come straight from the SEC. That means Form 4 filings, 13F filings and XBRL financial data on EDGAR. Government filings come from the public STOCK Act and Office of Government Ethics disclosures. The market-wide headlines on the market line also come from the public headline feeds CNBC, MarketWatch and Yahoo Finance publish, shown as the headline, the source and a link to the article. Splits, dividends, and the financial statements on each ticker page come from the vendor's reference data. The 8-K filings on EDGAR are read for the items that move a price. Five years of history is loaded for every stock. So the 200-day and 52-week checks rest on real history. Options flow is not part of the product.

Do I need an account?

Not for the first 24 hours. Tap any green button and you're in, with no email and no password. To keep going, create a free account with Google, Apple, or your email. There is no password to make up.

Is this investment advice?

No. It is a screening tool that scores stocks on the chart, the company's own results, and the news and filings. It does not know your situation and it is not a recommendation to buy or sell anything. Please do your own research.

The price on this page is delayed at least 15 minutes. The share count and the filings are shown as filed.